The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/folinic acid (FA) in refractory advanced high-grade neuroendocrine cancer (HG-NEC) of gastroenteropancreatic (GEP) or unknown origin.
 
Medhavi Gupta
No Relationships to Disclose
 
Minsig Choi
No Relationships to Disclose
 
Robert A. Ramirez
Stock and Other Ownership Interests - Advanced Accelerator Applications (I); Advanced Accelerator Applications (I); Advanced Accelerator Applications (I); Advanced Accelerator Applications (I)
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; bioTheranostics; bioTheranostics; bioTheranostics; bioTheranostics; Novartis; Novartis; Novartis; Novartis
Speakers' Bureau - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck
Research Funding - AADi (Inst); AADi (Inst); AADi (Inst); AADi (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Kristopher Attwood
No Relationships to Disclose
 
Sarbajit Mukherjee
Research Funding - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
 
Renuka V. Iyer
Honoraria - Ipsen; Ipsen; Ipsen; Ipsen
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen; Lexicon; Lexicon; Lexicon; Lexicon; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis; Novartis
Research Funding - Cleveland BioLabs (Inst); Cleveland BioLabs (Inst); Cleveland BioLabs (Inst); Cleveland BioLabs (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)